Introduction
With 1.6 million deaths expected annually, lung cancer is the most common cause of cancerrelated death worldwide in both men and women. Currently, lung cancers are classified into nonsmall cell lung cancers (NSCLCs), which account for approximately 80% of cases, and small cell lung cancers representing the remaining 20%. Although in the last decade we witnessed an impressive advancement in the understanding the molecular mechanisms underlying the development and progression of NSCLC, the prognosis of patients with advanced disease is still disappointing, with 5-year survival rates of less than 5%, lower than many other leading cancer sites. 1 In this scenario, the discovery of targetable genetic mutations that drive distinct subsets of NSCLC has successfully paved the way for personalized therapy in patients harboring specific actionable molecular alterations with astounding clinical results.
those with adenocarcinoma histology. [4] [5] [6] However, the presence of EGFR mutations cannot be ruled out only on the basis of clinical characteristics.
It is noteworthy that EGFR mutations are typically non-overlapping with other oncogenic driver mutations found in NSCLC (e.g. KRAS, ALK, ROS1, MET, HER2, BRAF, NTRK1) which make EGFR-mutant (EGFRm) NSCLC a distinct disease entity. 7 EGFR-activating mutations are included in a wide spectrum of genetic alterations, principally inframe deletions, in-frame duplications/insertions, and point mutations. 3, 8 Altogether, frame deletions in exon 19 at the LeuArgGluAla sequence (E746-A750), and the exon 21-point mutation Leu858Arg (L858R), represent 85-90% of all EGFR mutations in NSCLC. Additional 'uncommon' mutations have been reported, including G719X in exon 18 (G719C, G719S, G719A), L861Q in exon 21, and S768I in exon 20. However, the predictive significance of these mutations to treatment with EGFR-TKI is still unclear, though data reported in literature so far seem to confirm a positive predictive role also for uncommon mutations. 9 On the other hand, exon 20 frame insertions, along with de novo T790M point mutations in exon 20 are responsible for primary resistance to EGFR-TKIs. [10] [11] [12] Clinical trials evaluating treatment-naïve patients with advanced NSCLC harboring sensitizing EGFR mutations treated with gefitinib, erlotinib or afatinib, showed a marked superiority in favor of EGFR-TKIs compared with platinum-based chemotherapy in terms of objective response rate (ORR), progression-free survival (PFS) and quality of life. [13] [14] [15] Afatinib was also associated with a statistically significant improvement in overall survival (OS) in patients with the del19 EGFR mutation, 16 though data from the LUX-lung 7 trial (a phase IIb trial comparing the activity of gefitinib and afatinib as upfront therapy for advanced EGFR-mutant NSCLC) showed that the differences in PFS, OS, time to treatment failure, and ORR with afatinib and gefitinib were largely unaffected by mutation type. 17 Unfortunately, despite the initial response to treatment, virtually all patients develop acquired resistance (AR) to treatment, which occurs typically within 9-14 months. In order to overcome such resistance a number of third-generation EGFR-TKIs have been designed and are under clinical evaluation. The aim of this review is to discuss emerging data regarding the third-generation EGFR-TKI osimertinib against the EGFR T790M mutation in the treatment of patients with advanced NSCLC.
Mechanism of resistance to first and second-generation EGFR-TKIs
Despite the inhibition of the mutated form of EGFR being one of the most successful examples of targeted therapy in NSCLC, the prognosis of these patients still remains unfavorable because, in addition to primary or intrinsic resistance, almost all patients who initially benefited will develop AR to EGFR-TKIs. Several mechanisms of either intrinsic or AR to EGFRTKIs have been described so far and many other are still unknown. Regarding pathogenesis, these mechanisms can be schematically divided in EGFR-dominant (secondary mutation) or EGFR-nondominant (bypass tracks with activation of other signaling pathways or phenotypic change). Overall, approximately 60% of AR cases are due to the secondary T790M mutation in exon 20 of the EGFR gene, followed by other EGFR mutations such as C797S, activation of alternative signaling pathways (such as MET or HER2 amplifications and secondary mutation of PI3KCA or BRAF), aberrance of the downstream pathways (KRAS mutations, and loss of PTEN), impairment of the EGFR-TKIs-mediated apoptosis (BCL2-like 11/BIM deletion polymorphism) and histological transformations. [18] [19] Primary resistance to EGFR-TKIs Although many mechanisms are not completely understood, intrinsic resistance, defined as an immediate ineffectiveness of EGFR-TKIs, is often due the presence of a nonsensitive EGFR mutation. The most important EGFR mutations that generate TKI resistance are represented by exon 20 insertions or duplications, which account for 1-10% of the entire group of EGFR mutations. Most of these insertions occur between amino acids 767 and 775, and their preferential location is the C-helix (A767 to C775). 20 This region is crucial in orienting the kinase into a state that controls both the ATP and the EGFR-TKI binding. The result is that the majority of exon 20 insertion mutations regulate the kinase domain conformation into an active position and reduce the affinity for EGFR-TKIs. 21 journals.sagepub.com/home/tam 389
Although the gatekeeper T790M mutation is recognized as the most common mechanism of AR, it has also been associated with primary resistance and in vitro studies have demonstrated transformational potential when T790M is concurrently expressed with an EGFR-TKI-sensitizing mutation. 22 Regarding the allelic frequencies of this mutation in treatment-naïve tumors, with the conventional Sanger sequencing methods, this value has been reported as rather low. Interestingly, recent studies conducted using more sensitive techniques such as next-generation sequencing, locked nucleic acid polymerase chain reaction (PCR) and high-performance liquid chromatography, have reported higher frequency rates of T790M mutations in EGFR-mutant NSCLC pretreatment tumors (35%, 38% and 79% respectively). [23] [24] [25] Another EGFR mutation that occurs in the extracellular domain, consisting of in-frame deletion of exons 2-7 (namely EGFR vIII), has been associated with EGFR-directed therapy failure. This form of resistance relies on structural changes in the EGFR protein, ultimately leading to constitutive activation of EGFR vIII. 26 Intrinsic resistance may also be caused by concurrent molecular or genetic alterations that compromise the EGFR-TKI response in patients with sensitizing EGFR mutations. An example is represented by the pro-apoptotic Bcl-2 family member BIM, that is a crucial mediator of EGFR-TKI-induced apoptosis. 27 35 Importantly, the acquisition of the T790M mutation leads to an increased affinity of EGFR for ATP, ultimately resulting into the displacement of ATP-competitive TKIs. 35 Interestingly, even though the reason is still unclear, patients with disease progression due to a secondary EGFR T790M mutation, tend to have a more indolent natural history and longer post-progression survival as compared with patients with T790M-negative tumors. 36 To date, two theories have been proposed in order to explain the development of these second mutations: subcloning and induced mutation/acquisition. 37 In this respect, although this secondary mutation is rarely found in TKI-naïve tumors, resistant clones may be selected following prolonged exposure to TKIs and are detected in roughly 60% of EGFR-TKIs-treated patients. 25, 38 T790M mutation can also coexist with different EGFR mutations, such as L858R and D761Y and this combination leads to lung cancer cell survival. 39 Regarding the relationship between the T790M mutation and the activity of the irreversible EGFR-TKI, afatinib, a preclinical study showed a certain grade of activity in EGFR T790M-positive NSCLC cell lines; however no evidence of survival benefit has been reported with afatinib after failure of platinum-doublet chemotherapy and a first-generation EGFR-TKI. [40] [41] Once it was established that T790M represents the major mechanism of AR to first-and secondgeneration EGFR-TKIs and that third-generation EGFR-TKIs with a specific activity against T790M such as osimertinib and rociletinib (CO1686) showed to be very effective also in this subgroup of patients, it was clear that re-biopsy at disease progression, whenever possible, is crucial in order to make the appropriate decision on management of these patients. [42] [43] Not surprisingly, several mechanisms of AR to third-generation EGFR-TKIs osimertinib and rociletinib, in vitro and in vivo, have recently been discovered. Niederst and colleagues analyzed cell-free DNA by next-generation sequencing (NGS), of 15 patients with resistance to osimertinib, and identified different genotypes before and after treatment. 44 The most common was acquired C797S plus T790M mutation genotype (40%), followed by T790M mutation without the C797S mutation (33%) and loss of the T790M mutation in absence of the mutation C797S (27%). 44 In these cases, proliferation of cancer cells is still EGFR-dependent but, under selective pressure of EGFR-TKIs, these cells may develop tertiary mutations in the EGFR gene, such as C797S.
Beyond T790M, rare EGFR resistance point mutations have been identified (<10% of patients), including T854A, D761Y, and L747S; however, the number of cases is extremely limited and the underlying mechanism is still unclear. [45] [46] Activation of alternative signaling pathways (e.g. MET, HER2, BRAF, PI3KA, IGFR1) and phenotypic transformation (epithelial to mesenchymal transition and small cell transformation) represent other common mechanism of AR to EGFR-TKIs but are not the subject of this review and so will not be discussed.
Liquid biopsy in NSCLC
The eligibility for treatment with osimertinib in advanced NSCLC requires tumor genotyping for EGFR and the presence of T790M resistance mutation. Until recently, molecular profiling of NSCLC was based only on tumor biopsy but the landmark for the detection of tumor genetic alterations is rapidly and excitingly changing. A new perspective for molecular tumor characterization is represented by the analysis of circulating tumor DNA (ctDNA) that provides a non-invasive alternative approach to tumor biopsy.
The use of liquid biopsy has multiple potential applications and advantages. It represents a fast and non-invasive method applicable for early diagnosis, assessment of prognosis, monitoring of tumor burden and identifying AR during the treatment, 47 while repeating tissue biopsy to evaluate genomic tumor evolution at the time of disease progression or even during therapy is problematic, expensive and unsafe and may not be reflective of tumor heterogeneity. 48 Several methods are available for the blood-based EGFR mutational status analysis which must be highly sensitive because of the low frequency of ctDNA in blood compared with germline cellfree DNA. These methods include: allele-specific PCR platforms like the Cobas® EGFR Mutation Test (Roche, Basel, Switzerland) and the Therascreen® EGFR amplification refractory mutation system (ARMS) assay (Qiagen, Hilden, Germany), digital assays including the droplet digital PCR (ddPCR), as well as the beads, emulsions, amplification and magnetics (BEAM)ing dPCR technique (Sysmex Inostics, Hamburg, Germany). Moreover, NGS is evolving to be applicable for ctDNA analysis (Amplicon-based targeted NGS as well as Captured-based Targeted NGS), offering efficiently large spectrum genotyping analysis starting from a limited amount of material. 49 In recent years many studies have shown that ctDNA can be used to identify and quantify mutations in solid cancers. In 2009, Rosell and colleagues analyzed 164
samples of ctDNA extracted from the serum of patients, suffering from NSCLC with activating mutations of the EGFR determined on tumor tissue, yielding a sensitivity equal to 59.2%. 15 Later, Liu and colleagues identified the same activating mutation in ctDNA extracted from plasma compared with that detected on the tissue sample by using the ARMS platform in 67.5% of the cases analyzed. 50 In the last decade, several studies have shown that it is feasible to detect mutations in the plasma or serum of NSCLC patients with a sensitivity ranging between 46-80% and with a high level of specificity and concordance with tumor tissue analysis. [50] [51] [52] [53] [54] [55] [56] A recent systematic review and meta-analysis including 25 studies on a total of 2605 patients showed, for a blood-based test, a sensitivity, specificity, and concordance rate of 0. Recently Sacher and colleagues have analyzed by ddPCR (Bio-Rad/Molecular MD, California, USA) ctDNA of 120 patients at the time of diagnosis and 60 patients at the time of AR to an EGFR-TKI, demonstrating a sensitivity of plasma genotyping of 82% for EGFR exon 19 deletion, 74% for the L858R mutation, 77% for the T790M mutation, and 64% for the KRAS G12X mutation, compared with tumor biopsy molecular analysis. 58 Another recent study focused on EGFR mutation-positive NSCLC patients with AR to EGFR-TKIs identified TKI-sensitizing and T790M mutations in plasma of 120 (46.2%) and 75 (28.8%) patients, respectively. 59 T790M was detected in 56.7% of patients with plasma positive for TKI-sensitizing mutations. The concordance for mutation detection at the time of resistance by ddPCR in plasma compared with tumor tissue or malignant fluid specimens, evaluated on 41 patients with paired samples, was 78.0% for TKI-sensitizing mutations and 65.9%
for T790M (identified especially in larger tumors and more heavily treated tumors). 59 The ability of real-time based methods (Cobas, Therascreen, ddPCR and BEAMing dPCR) to detect EGFR mutations, including T790M, has been assessed using plasma samples collected in the phase I part of AURA trial. 60 Liquid biopsy is feasible and increases the number of patient eligible for target therapy but several issues are still open. More efforts are required to increase sensitivity, to avoid artifacts and reduce false positive, and finally translate the entire potential of ctDNA analysis in the clinical management of cancer patients.
Pharmacodynamics and pharmacokinetics
The most common sensitizing mutations of EGFR, including in-frame deletions of exon 19 and the point mutation L858R, have been demonstrated to reduce ATP affinity and increase the sensitivity of mutant receptors to competitive inhibitors. 65 Consistently, gefitinib and erlotinib show a dramatic clinical benefit in patients with EGFR exon 19 or exon 21-mutated NSCLCs. 66 The missense T790M variant in exon 20 of EGFR with the primary activating mutation of the EGFR allele results in a significantly increased affinity of mutant EGFR for ATP. 35 In detail, pharmacokinetic analyses showed the Michaelis-Menten constant (Km) for ATP of respectively 8.4 ± 0.3 μM, 5.2 ± .02 μM and 148 ± 4 μM in the L858R/ T790M mutant, wild-type and single L858R mutant receptor. 35 As a consequence, the T790M mutation markedly reduces the potency of EGFR competitive inhibitors, representing the primary mechanism of T790M-mediated first-generation TKI resistance.
Osimertinib (TAGRISSO™, AZD9291; AstraZeneca, London, UK) is a mono-anilinopyrimidine, orally available, irreversible, thirdgeneration EGFR-TKI, which inhibits EGFR, via the C797 amino acid covalent bond, both sensitizing mutations (exon 19 deletion, L858R) and double mutants harboring T790M at a nine-fold lower concentration compared with wild-type EGFR. In vitro assays showed that osimertinib also possesses a certain grade of activity at clinically relevant concentration against ERBB2, ERBB3, ERBB4, BLK and ACK1. Consistently, preclinical models involving NSCLC cell lines and tumor xenografts showed that osimertinib exerts an impressive activity against those tumors harboring L858R, exon 19 deletions alone or in coexistence with T790M mutations. Of note, two of its metabolites AZ7550 and AZ5104, which are circulating at approximately 10% of the mother compound, retain a comparable inhibitory profile on EGFR mutations to osimertinib. AZ7550 showed also a similar potency to the original molecule while AZ5104 exhibits an eightfold greater potency against exon 19 deletion and T790M mutation, and up to 15-fold higher against wild-type EGFR. 30 Following a single oral administration, osimertinib exhibits a linear pharmacokinetics, the area under the plasma concentration-time curve (AUC), along with maximal plasma concentration (Cmax) and minimal concentration (Cmin) increases in a dose proportional manner over the 20-240 mg dose range. Osimertinib is given once daily, with a three-fold body accumulation after single administration, which results in steady-state exposure achieved in 22 days of dosing, reaching a mean volume of distribution of approximately 986 l. Importantly, the AUC of osimertinib derivative compounds AZ5104 and AZ7550 is approximately 10% of the exposure of osimertinib. Of note, pharmacokinetic exposure does not substantially differ Clinical efficacy of osimertinib in NSCLC On the heels of promising preclinical data, the phase I/II AURA trial [ClinicalTrials.gov identifier: NCT01802632] was conducted in order to assess the safety and efficacy of osimertinib in patients with advanced EGFR-mutant (EGFRm) NSCLC who progressed on or following a first-or secondgeneration EGFR-TKI (Figure 1 ). A total of 253 patients were enrolled in this study. Of them, 33 were included in the dose-escalation portion, and 222 in the dose-expansion cohort that evaluated five doses ranging from 20-240 mg daily. All patients had received at least one EGFR-TKI prior to osimertinib, while 80% had also received prior cytotoxic chemotherapy. Overall, 138 of the 222 patients (62%) enrolled in the expansion cohorts had a documented T790M mutation whereas it was not detected in tumors from 62 patients in those cohorts (28%). For the remaining 22 patients, EGFR mutational status was unknown (10%). Overall, osimertinib showed a promising clinical activity with a an ORR of 51%. Of 239 patients evaluable for response, 123 (51%) experienced a partial response (PR, n = 122) or a complete response (CR, n = 1) and 78 (33%) had stable disease, while only 34 (14%) had progressive disease (PD). Importantly, in patients with a documented T790M mutation at central testing, the ORR was 61%, with a disease control rate (DCR) of 95%. On the other hand, the subgroup of patients who were negative for T790M experienced inferior ORR (21%) and DCR of (61%) compared with the T790M-positive counterpart. The median PFS was 8.2 months. Again, patients harboring a T790M mutation had a median PFS of 9.6 months, whereas those without the mutation had a lower median PFS of 2.8 months. No difference in ORR was observed between Asian and Western patients. 42 In view of increasing toxicities observed at the 160 mg and 240 mg doses, and similar These findings have been further enlarged by the preliminary results of the expansion cohort of the AURA trial and the phase II AURA2 trial ( Figure  1 ). In the expansion cohort of AURA, which involved 201 patients with T790M-positive locally advanced or metastatic NSCLC, osimertinib was associated with an ORR assessed by an independent review committee (ICR) of 58% and a DCR of 92%. 67 In the AURA2 trial, an openlabel, single-arm phase II study, 210 patients with advanced NSCLC and harboring the T790M mutation as assessed by central testing confirmation (Cobas TM EGFR mutation test) received osimertinib at the recommended dose of 80 mg. ORR assessed by ICR was 70% and DCR was 92%. The median duration of response was 11.4 months (95% CI 9.0-not calculable). Notably, data for 70 of these patients were censored at the time of data cutoff and the proportion of patients remaining in response was 76% and 59% at 6 and 9 months respectively, and 48% at 12 months. Median PFS as assessed by blinded independent central review was 9.9 months (95% CI 8.5-12.3) and the proportion of patients estimated to be progression-free at 6, 9 and 12 months was respectively 71%, 56% and 44%. 68 More recently, updated results from the T790M-positive cohort of the AURA phase I trial, along with a pooled analysis of phase II studies ( (Figure 1 ).
Safety and tolerability of osimertinib
First-and second-generation EGFR-TKIs have been tested on a large number of patients over the last decade, meanwhile most studies involving third-generation TKIs, including osimertinib are currently ongoing, and safety data are still immature. However, even though long-term follow up is required for a precise assessment on safety, osimertinib seems to have an acceptable toxicity profile and tolerability, better if indirectly compared with first-and second-generation EGFR-TKIs.
In the dose-escalation cohort of the phase I AURA trial, osimertinib displayed a satisfactory safety profile, and no dose limiting toxicities were observed at any dose level tested (ranging from 20-240 mg daily). The overall incidence of any grade of adverse event (AE) was 96%, with 32% of patients experiencing grade 3-5 AEs. AEs leading to dose reduction or drug withdrawal were observed in 7% and 6% of patients, respectively. Serious AEs considered to be treatment-related, as assessed by the site investigator, occurred in 6% of patients. Notably, no differences in the severity or frequency of AEs were observed between Asian and Western patients. The most common AEs were diarrhea (47%), rash (40%), nausea (22%), and decreased appetite (21%). Furthermore, 6 cases (2.4%) of pneumonitis-like AEs occurred, and resolved following osimertinib discontinuation. Additionally, 11 patients (4.3%) developed prolongation of the QTc interval while 6 patients (2.4%) experienced hyperglycemia during osimertinib treatment. 42 The expansion cohort study and the AURA2 trial showed similar results in terms of safety and tolerability. In a pooled analysis of these studies the most common AEs of any grade with osimertinib 80 mg/daily were diarrhea (42%), rash (41%), dry skin (31%) followed by paronychia (25%). AEs requiring dose reduction or drug discontinuation manifested 4.4% and 5.6% of patients, respectively. A prolonged QTc interval (2.2%) and neutropenia (1.9%) were the most common event associated with dose reduction or discontinuation. Of note in both trials, four cases of deadly interstitial lung disease occurred that was considered eventually related to osimertinib by the investigator. 69 More recently, osimertinib confirmed a satisfactory safety profile also in the AURA3 trial. In this study 273 out of 279 (98%) patients reported at least one AE. In the osimertinib arm, the most commonly reported AEs were diarrhea (41%), rash (34%), dry skin (23%), and paronychia (22%). AEs of grade ⩾3 occurred in 16 patients (6%) and included diarrhea (1%), anemia (1%), decreased appetite (1%), skin rash (1%) and interstitial lung disease (1%). Of note, interstitial lung disease-like AEs were recorded in 10 patients (4%) in the osimertinib group, with 9 events of grade 1 or 2 in severity and 1 death. Compared with platinum-pemetrexed chemotherapy, osimertinib was associated with a lower rate of AEs leading to permanent discontinuation (7% versus 10%). 70 
Efficacy of osimertinib in EGFR-mutant NSCLC brain metastases
Central nervous system (CNS) failure is a common event during treatment with EGFR-TKIs, probably reflecting the long survival benefit achieved with targeted therapies. In front of poor penetration rates of first-generation EGFR-TKIs across the blood-brain barrier (BBB), CNS response occurs in approximately 80% of patients with pre-existing brain metastases (BMs) treated with upfront gefitinib or erlotinib, suggesting a significant intracranial efficacy of these drugs. Unfortunately, after initial intracranial response 26-33% experience disease progression in CNS which associates with a very poor prognosis. 73 Whether osimertinib exerts activity also against brain metastasis is still poorly addressed and data B Ricciuti, S Baglivo et al.
journals.sagepub.com/home/tam 397 are lacking. In an early preclinical study involving an EGFRm BM xenograft mouse model, osimertinib distribution into the brain was 10-fold higher compared with gefitinib at clinically relevant doses, and resulted in a marked shrinkage of brain lesions. 74 These data have been further corroborated by Ballard and colleagues who confirmed a greater penetration of osimertinib across the BBB than gefitinib, rociletinib (CO-1686), or afatinib, and at clinically relevant doses in a mouse model. Worthy of note, osimertinib was associated with a sustained tumor regression in an EGFRm PC9 mouse BM model; conversely the third-generation EGFR-TKI rociletinib, did not achieve tumor regression. 75 Consistent with these findings, our group has recently published the cases of two radiotherapy-naïve patients with EGFRm and T790M-positive pretreated advanced NSCLC and BMs who responded to osimertinib. There was one patient that had a solitary brain lesion at diagnosis and was treated with upfront erlotinib that led to a prolonged control of CNS disease and no need of cranial radiation. Upon documentation of T790M-positive disease progression (extra-and intracranial), brain radiotherapy was withheld in favor of osimertinib, which allowed a re-response in the brain and in extracranial sites, suggesting that osimertinib crosses the BBB and overcomes a T790M-mediated resistance in the CNS. On the other hand, the second patient developed CNS disease following T790M-mediated resistance to gefitinib. At the time of progression, the patient was switched to osimertinib from which they achieved an impressive intracranial response. Both cases confirmed the clinical activity of osimertinib in BMs from T790M-positive NSCLC. Overall, this report may suggest that delaying cranial radiation in favor of a third-generation EGFR-TKI osimertinib, might represent an excellent therapeutic alternative for radiotherapy-naïve patients progressing in the brain on a first-or second-generation EGFR-TKI, especially in view of the long life expectancy these patients usually encounter. 76 More were symptomatic, of which 3 had improvement in neurological symptoms, while 1 had no change and 2 were not evaluable. Notably, of 9 patients with pre-dose and cycle 2 day 1 CSF timepoint samples, 8 had a significant decrease in EGFRm DNA copy, which was >50% in 5 patients. 78 Taken together, these data support the hypothesis that osimertinib can actually cross the BBB and be effective against CNS metastases from EGFRm NSCLC. Certainly these findings are still immature and should be interpreted with caution, however are very encouraging.
Regulatory affairs
In November 2015, the US FDA granted osimertinib approval for the treatment of patients with T790M-positive advanced NSCLC who had progressed on or following first-or second-generation EGFR-TKIs (gefitinib, erlotinib, afatinib) accompanied by the approval of a companion diagnostic test (Cobas® EGFR Mutation Test v2; Roche). Subsequently, osimertinib was registered with the same indication in Europe, Japan and South Korea. Of note, in Europe tissue-and blood-based EGFR mutation testing before treatment with osimertinib were allowed concurrently to the approval of the drug. Conversely, in the US the blood-based testing for EGFR mutations has been available for determining osimertinib eligibility since September 2016, but is not feasible in case tissue sampling.
Conclusion and future perspectives
EGFR-TKIs represent the mainstay of first-line therapy for patients with advanced NSCLC harboring sensitizing EGFR mutations. Nevertheless, resistance to treatment invariably occurs, generally within 1 year. Patients with disease progression after first-line TKIs have been traditionally switched to a platinum-doublet-based secondline chemotherapy, which unfortunately yields a disappointing ORR of 30%, considerably lower compared with 51% and 71% reported with osimertinib in phase I and II studies, respectively. 79, 80 Recently, the results of the phase III AURA3 trial have been published and confirmed an astounding clinical efficacy of osimertinib compared with platinum-doublet chemotherapy in terms of ORR and DCR (71% versus 31% and 93% versus 74%, respectively). [2] [3] Taken together, these data suggest the use of osimertinib upon documented T790M-mediated disease progression after therapy with EGFR-TKIs of the precedent generation, setting aside cytotoxic platinum-based chemotherapy as third-line treatment (Table 2) .
Osimertinib is also being evaluated in a first-line setting within the phase III clinical trial FLAURA which compares osimertinib with gefitinib/ erlotinib in EGFRm treatment-naïve advanced NSCLC. This study is expected to provide novel data that might elucidate whether osimertinib can gain a role as upfront therapy, as T790M-positive clones have been proven to coexist in untreated patients with an EGFR-sensitizing mutation. Finally, osimertinib is also being studied as part of combination therapy. In the phase Ib trial TATTON [ClinicalTrials.gov identifier: NCT02143466] osimertinib was administered in combination with either darvalumab (anti PD-L1), selumetinib (MEK inhibitor) or savoltinib (MET inhibitor). Preliminary results from the osimertinib plus darvalumab cohort showed an ORR of 67% (6/9) and 21% (3/14) in EGFR-TKI pretreated patients with T790M positive and T790M negative NSCLC, respectively, and 70% (7/10) in EGFRm treatment-naïve patients. 79 However, the combination resulted in more toxicity, especially with immunotherapy, with interstitial lung disease and diarrhea occurring with higher incidence and grade in an osimertinib-darvalumab association then osimertinib or darvalumab alone. 79 Interestingly, osimertinib is also being evaluated in combination with dasatinib for the treatment of patients with EGFRm NSCLC. Dasatinib is a potent, orally available Abelson murine leukemia viral oncogene homolog 1/Proto-Oncogene Tyrosine-Protein Kinase Src (ABL1/SRC) TKI, approved for the first-line treatment of chronic myeloid leukemia and in patients with imatinibresistant disease and is being studied in patients with advanced solid tumors. Recently, researchers identified Cripto-1 overexpression as a mechanism of intrinsic resistance to EGFR-TKIs via activation of the SRC oncogene. 80 On this basis, an open label, nonrandomized, phase I/II trial evaluating the combination of osimertinib and dasatinib in TKI-naïve, advanced, EGFRm NSCLC has been designed, and is currently recruiting participants [ClinicalTrials.gov identifier: NCT02954523]. Despite the impressive clinical results reported so far, patients with T790M-positive advanced NSCLC who initially respond to osimertinib constantly develop resistance to treatment, with preliminary data showing a PFS ranging from 9.7-11 months. 42, [69] [70] In consideration of the clinical efficacy showed so far and the favorable safety profile, osimertinib is expected to become the standard treatment for patients with EGFRm and documented T790M mutation advanced NSCLC who progress on a first-or second-generation EGFR-TKI. Ongoing clinical trials will further clarify whether osimertinib can carve out a role in a first-line setting or in combination with other agents.
Along with osimertinib, several third-generation EGFR-TKIs are under clinical investigation. Rociletinib is a small mutant-selective, covalent inhibitor of both the activating EGFR mutations (exon 19 deletions and L858R) and the resistance mutation T790M. Despite initial promising results in terms of ORR (59%) and DCR (93%) among patients with centrally confirmed T790M-positive tumors in a phase I/II trial, 43 the updated 'confirmed' response rates were extremely disappointing, reaching 34% at a 625 mg twice daily dose and 28% at a 500 mg twice daily dose in patients with T790M-positive NSCLC, with a median duration of response of 9 months for both doses (Clovis presentation at the JP Morgan Healthcare Conference, 13 January 2016). Following the achievement of these data, the developmental program of rociletinib has been recently discontinued.
EGF816 is another third-generation covalent EGFR inhibitor with potent inhibitory activity against the most common sensitizing del19 and L858R mutations and resistant T790M mutants. 81 In preclinical models, EGF816 proved to be more efficacious than earlier generation EGFR inhibitors. 
